plaque Clinical Trials

120 recruitingLast updated: July 25, 2026

There are 120 actively recruiting plaque clinical trials across 45 countries. Studies span Not Applicable, Phase 3, Phase 2, Phase 1, Phase 4, Early Phase 1. Top locations include Beijing, Beijing Municipality, China, Shanghai, Shanghai Municipality, China, Edmonton, Alberta, Canada. Updated daily from ClinicalTrials.gov.


plaque Trials at a Glance

120 actively recruiting trials for plaque are listed on ClinicalTrialsFinder across 6 cities in 45 countries. The largest study group is Not Applicable with 42 trials, with the heaviest enrollment activity in Beijing, Shanghai, and Edmonton. Lead sponsors running plaque studies include Bristol-Myers Squibb, Novartis Pharmaceuticals, and Colgate Palmolive.

Treatments under study

About plaque Clinical Trials

Looking for clinical trials for plaque? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new plaque trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about plaque clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 120 trials

Recruiting
Phase 3

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

Plaque Psoriasis
Bristol-Myers Squibb3,040 enrolled394 locationsNCT07116967
Recruiting
Phase 3

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

Plaque Psoriasis
Takeda110 enrolled40 locationsNCT07250802
Recruiting

A Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD

Metabolic Dysfunction-Associated Steatotic Liver DiseasePlaque Psoriasis
Novartis Pharmaceuticals150 enrolled3 locationsNCT07683065
Recruiting
Phase 1

A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

Hidradenitis SuppurativaPsoriatic ArthritisAxial Spondyloarthritis+1 more
UCB Biopharma SRL20 enrolled14 locationsNCT06888193
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis

Moderate to Severe Plaque Psoriasis
UCB Biopharma SRL168 enrolled50 locationsNCT06425549
Recruiting
Not Applicable

Modifying PEST for Psoriatic Arthritis Screening

Psoriatic ArthritisPlaque Psoriasis
Novartis Pharmaceuticals502 enrolled30 locationsNCT06382051
Recruiting
Phase 3

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis
Bristol-Myers Squibb366 enrolled129 locationsNCT06979453
Recruiting
Not Applicable

Oil Pulling Reduction

Dental PlaqueGingival Inflammation and BleedingGood Health
The University of Texas Health Science Center at San Antonio120 enrolled1 locationNCT07706647
Recruiting
Phase 1Phase 2

A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)

Alzheimer s DiseaseBeta-AmyloidProdromal Alzheimer's Disease+2 more
AC Immune SA304 enrolled26 locationsNCT05462106
Recruiting
Phase 2

Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis

Plaque Psoriasis
Oruka Therapeutics, Inc.160 enrolled34 locationsNCT07474792
Recruiting

Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis

Plaque Psoriasis
AbbVie700 enrolled81 locationsNCT07039110
Recruiting
Phase 3

A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).

DementiaAlzheimer DiseasePlaque, Amyloid
Eli Lilly and Company550 enrolled59 locationsNCT07602582
Recruiting
Phase 1Phase 2

Prospective Management of Plaque Instability With Statins and Extra Folic Acid

carotid atherosclerotic plaque
Ruijin Hospital180 enrolled1 locationNCT07680595
Recruiting
Phase 2

Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis

Plaque Psoriasis
Oruka Therapeutics, Inc.160 enrolled36 locationsNCT07290569
Recruiting
Phase 2

An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis

Plaque Psoriasis
Oruka Therapeutics, Inc.240 enrolled24 locationsNCT07449702
Recruiting
Phase 3

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Moderate to Severe Plaque Psoriasis

Moderate to Severe Plaque Psoriasis
Zhejiang Wenda Pharma Technology LTD.375 enrolled1 locationNCT07672561
Recruiting
Not Applicable

Plaque Removal Efficiency in Children With Specific Learning Disabilities

Oral HygieneDental PlaqueSpecific Learning Disabilities
Alanya Alaaddin Keykubat University70 enrolled1 locationNCT07611942
Recruiting
Phase 4

PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis

Atherosclerotic PlaqueIntracranial AtherosclerosisIntracranial Artery Stenosis
Peking Union Medical College Hospital300 enrolled19 locationsNCT06902740
Recruiting
Phase 3

Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis

Moderate-to-severe Chronic Plaque Psoriasis
Vanda Pharmaceuticals300 enrolled4 locationsNCT07362017
Recruiting

Microplastics and Nanoplastics in Patients With Chronic Coronary Syndromes

Pollution; ExposureMicroplasticsNanoplastics+4 more
Azienda Ospedaliera "Sant'Andrea"120 enrolled6 locationsNCT07291609